MWB raises target for Drägerwerk stock from EUR 114.00 to EUR 130.00

Published on 10/05/2026 at 11:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached EUR 847.30 million and EBIT margin hit 5.40 percent. Drägerwerk stock costs EUR 117.40 on October 5, 2026 versus EUR 116.70.

Bauhaus-Konstruktivismus-Poster mit MEDIZINTECHNIK-Schriftzug und geometrischen Primärfarben — Drägerwerk AG & Co. KGaA Bauhaus-Poster Medizintechnik geometrische Formen Primärfarben Konstruktivismus DE0005550636, Illustration mit AI erstellt.

Drägerwerk stock (ISIN DE0005550636) was trading at EUR 117.40 at Lang & Schwarz on October 5, 2026, up 0.60 percent from the prior close of EUR 116.70. On August 31, 2026, MWB Research raised its price target from EUR 114.00 to EUR 130.00, according to Finanztrends.

Target moves above the market

The new target places the analyst valuation 10.73 percent above the Lang & Schwarz price, calculated from EUR 130.00 and EUR 117.40. That spread gives the analyst action a clear market reference, while the stock remains below the target level named by MWB Research.

The target change followed stronger operating indicators in the second quarter of 2026. wallstreetONLINE reported that revenue grew 8.50 percent on a currency-adjusted basis and that the EBIT margin increased from 2.60 percent to 5.40 percent in the second quarter.

Margins support the valuation

Dräger's investor-relations page sets fiscal 2026 revenue growth at 2.00 percent to 6.00 percent on a currency-adjusted basis and the EBIT margin outlook at 5.00 percent to 7.50 percent. The same page identifies medical technology and safety technology as the company's two operating markets, with products spanning acute-care equipment, gas detection and personal protection.

The second-quarter figures matter because the margin improvement came with revenue growth rather than a purely cost-led result. For investors, the key question is whether the higher profitability can persist while Dräger continues to expand its medical and safety technology businesses.

October results set the next test

Drägerwerk is scheduled to publish its third-quarter 2026 results on October 29, 2026, according to the company calendar reported by MarketScreener. That report will provide the next periodized check on revenue growth, operating margin and the 2026 outlook.

Stock remains below the target

Drägerwerk's market capitalization was EUR 2.2 billion as of October 5, 2026, while its 52-week range was EUR 64.50 to EUR 125.40. At EUR 117.40, the stock was 6.38 percent below its 52-week high, leaving the current quote close to the upper end of its annual range.

At 10:58 a.m. CEST on October 5, 2026, the Lang & Schwarz quote stood at EUR 117.40, plus 0.60 percent versus the prior close of EUR 116.70. The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.